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Abstract
Objectives To investigate knowledge and attitudes of different healthcare pro-
fessionals in UK towards infliximab and insulin glargine biosimilars
Methods UK medical consultants/registrars, nurses and pharmacists partici-
pated in anonymised, self-administered web-based survey distributed by profes-
sional associations.
Key findings There were 234 respondents: medical consultants/registrars (150),
nurses (58) and pharmacists (26). 76% of medical consultants/registrars, 84%
of pharmacists and 53% of nurses understood what biosimilars were. Medical
consultants/registrars and pharmacists had safety and efficacy concerns when
switching patients compared to initiation. Nurses had similar levels of safety
and efficacy concerns about initiation.
Conclusion Healthcare professionals were more comfortable with the initiation
of biosimilars than switching current patients. Medical consultants/registrars
and pharmacists were more informed than nurses.
Introduction
Biosimilars are copies of approved and patent-expired
biological medicines. In a financially constrained health
system such as the UK National Health Service, the lower
cost of biosimilars presents a significant potential cost
saving.[1] Up to February 2018, 38 biosimilars, corre-
sponding to 14 molecules, were licensed in Europe.[2] The
more indications for biosimilars that are licensed, the
more healthcare professionals (HCPs) are potentially pre-
scribing them, but the relatively rapid introduction of
biosimilars has resulted in a knowledge gap amongst
HCPs.[3,4] There are parallels with the early generics mar-
ket; HCPs required a good understanding and knowledge
before they were comfortable prescribing generics, so, it is
likely that the same applies to biosimilars.[4] Our study
aimed to explore this potential gap in knowledge for
infliximab and insulin glargine biosimilars and investigate,
attitudes and practice towards these biosimilars amongst
UK medical consultants, nurses and pharmacists.
Methods
This was an anonymised, self-administered web-based
survey among UK medical consultants/registrars, nurses
and pharmacists specialised in dermatology, diabetology,
gastroenterology or rheumatology, conducted between
August 2016 and January 2017.
The following associations were emailed and asked in
turn to email potential participants an invitation letter
with a link to the web survey; British Society of Gas-
troenterology, the British Society of Paediatric Gastroen-
terology Hepatology and Nutrition, the Welsh
Association for Gastroenterology & Endoscopy, the Bri-
tish Society for Medical Dermatology, the British Society
for Paediatric Endocrinology and Diabetes, the Associa-
tion of British Clinical Diabetologists, the British Derma-
tological Nursing Group, the Scottish Society for
Rheumatology, the British Society for Rheumatology. This
was followed by a reminder email trail four weeks after
the initial email.
The survey questionnaire was developed from emerging
themes in the current literature on biosimilars.
Questions identified respondents’ professional discipline
and workplace setting and investigated their knowledge,
experience and opinions towards infliximab and insulin
glargine biosimilars. Response options were either closed
choices or Likert type scales. Responses were confidential
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with no personally identifying information; respondents
consented by clicking an ‘agree’ button preceding the sur-
vey. The web survey tool enabled only fully completed
responses to be submitted and utilised cookies to allow
only one response per computer. The survey was piloted
on a small number of HCPs and revised appropriately to
eliminate redundancy and difficult or ambiguous ques-
tions. The survey responses were collected and sum-
marised as number and percentage of responding HCPs
using Survey Monkey. The study was approved by the
Independent Peer Review Committee at Keele University.
Results
A total of 234 HCPs participated in the survey. The high-
est proportion of responses were from medical consul-
tants/registrars (64%) (n = 150) followed by nurses 25%
(n = 58). The lowest response, 11% (n = 26) was from
pharmacists. Most of the survey participants were general
hospital and tertiary centre-based HCPs (Table 1).
The majority, (76%, n = 115), of medical consultants/
registrars, nurses (53%, n = 31%) and pharmacists (84%,
n = 22) thought biosimilars were copies of biological
medicines. A minority of respondents (6%, n = 15)
(mainly nurses) stated that they had heard about biosimi-
lars but did not know what they were or had never heard
about biosimilars. A large proportion of the medical con-
sultants/registrars 80% (n = 121), pharmacists 80%
(n = 21), and 57% of nurses (n = 33) were aware that
biosimilars were available on their local formulary
(Table 1).
Only 14% of consultants/registrars and 19% of phar-
macists had major concerns about safety or concerns
which prevented them initiating a biosimilar. Similarly,
22% of consultants/registrars and 16% of pharmacists had
major concerns about efficacy or efficacy concerns which
prevented them initiating biosimilars. Twice as many
nurses had the same safety (42%) and efficacy (54%) con-
cerns (Figure 1).
When considering switching patients to a biosimilar,
nurses had similar levels of concerns about safety (52%)
and efficacy (63%) to initiation. In contrast, only 28% of
medical consultants/registrars and 38% of pharmacists
had concerns about safety and when initiating patients on
a biosimilar, with similar levels of concern about efficacy
when switching (34% and 50% respectively) (Figure 1).
Nearly all medical consultants/registrars (91%) and
nurses (96%) weighted robust pharmacovigilance studies
on biosimilars as the most important influence on their
decision to increase prescribing of biosimilars, whereas
97% of pharmacists weighted National Institute for
Health and Care Excellence (NICE) guidance as more
important. Medical consultants/registrars (27%) and
pharmacists (28%) weighted increased patient acceptabil-
ity as the least important of all the factors, whereas cost
was an important consideration (84%, 85%), respectively.
Nurses (32%) considered potential cost saving to the
respondents’ organisation as the least important of all the
factors.
Discussion
This survey highlighted a variance in the level of knowl-
edge and awareness of biosimilars between UK HCPs;
pharmacists had the highest level of knowledge and
awareness, followed by physicians, then nurses (Table 1).
Our study has some limitations. There were only a
small number of pharmacist respondents, which may
reflect the relative membership of the professional associ-
ations who supported the survey. It was not possible to
calculate the response rate as the total number of mem-
bers of the professional associations and societies are con-
fidential. We would estimate that our response rate was
relatively low.
Table 1 participants’ characteristics, knowledge and awareness
Consultants/
registrars
n = 150
Nurses
n = 58
Pharmacists
n = 26
Speciality
Dermatology 20 (13.3%) 41 (70.7%) 0 (0%)
Diabetology 49 (32.6%) 5 (8.6%) 4 (15.4%)
Gastroenterology 43 (28.6%) 2 (3.5%) 9 (34.6%)
Rheumatology 38 (25.3%) 10 (17.2%) 13 (50%)
Work setting
Primary care 0 (0%) 6 (10.4%) 3 (11.5%)
General hospitals 85 (56.7%) 47 (81%) 18 (69.3%)
Tertiary centres 63 (42%) 5 (8.6%) 2 (7.7%)
Other settings 2 (1.3%) 0 (0%) 3 (11.5%)
Which statement best describes what you understand a biosimilar to
be
A new biological
medicine
0 (0%) 2 (3.5%) 1 (3.8%)
A generic biological
medicine
30 (20%) 11 (19%) 1 (3.8%)
A counterfeit copy of a
biological medicine
2 (1.3%) 3 (5.2%) 1 (3.8%)
A similar copy of a
biological medicine
115 (76.6%) 31 (53.4%) 22 (84.8%)
I have heard about
biosimilars, but I do not
know what they are
2 (1.3%) 6 (10.3%) 0 (0%)
I have never heard
about biosimilars
1 (0.6%) 5 (8.6%) 1 (3.8%)
Are biosimilars on your local formulary?
Yes 121 (80.7%) 33 (57%) 21 (80.9%)
No 11 (7.3%) 7 (12%) 3 (11.5%)
I don’t know 18 (12%) 17 (29.3) 1 (3.8%)
Not applicable 0 (0%) 1 (1.7%) 1 (3.8%)
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The lower level of nurse knowledge may be related to the
fact that pharmaceutical marketing campaigns for biosimi-
lar manufacturers are directed to physicians rather than
nurses. Salem and Harvie’s Australian study showed that
nurses’ training in new products such as biosimilars is often
ad hoc and incomplete and they consequently had poor
knowledge of safety and efficacy of drug groups.[5] This is
of concern as nurses in many cases are responsible for
administering or supervising the patient’s pharmacological
regimen. The higher level of knowledge among pharmacists
is not surprising as they are experts in medicines.[6]
Initiating biologics (originator or biosimilar) often rests
with the responsible physician in consultation with the
patient. In the UK, NICE Key Therapeutic Topic (KTT15)
advised that biologics should not be automatically substi-
tuted by dispensing pharmacist.[7] Therefore, the decision
to switch to biosimilars (or to originator) is a multidisci-
plinary process involving the physician, patient, specialist
nurse and pharmacist.[8] Concerns about safety and efficacy
when switching patients to biosimilars were high in all
HCPs, but nurses had a higher level of (major) concerns
than physicians and pharmacists, about the safety and effi-
cacy of biosimilars when initiating in biologic na€ıve
patients. This may due to the fact that nurses had a lower
level of knowledge of biosimilars (Table 1) and are less well
informed about new medicines.[5] In French study, Beck
et al.,[9] showed that 67% of pharmacists had no concerns
about safety and efficacy of biosimilars in general and 52%
of pharmacists were in favour of substitution of branded
biologics to biosimilars; in France biosimilars substitution
by community pharmacists is allowed. These results are not
dissimilar to our results in relation to pharmacists’
attitudes to biosimilars. Zelenetz et al.,[10] also showed that
one-third of nurses indicated that they needed more infor-
mation on biosimilars before making a decision about
using and administering biosimilars.
Robust pharmacovigilance studies and guidance from
NICE or other reputable national bodies were most likely
to influence respondents to increase their utilisation and
prescribing of biosimilars. This is not surprising as inflix-
imab and insulin glargine biosimilars were only recently
approved (in 2015), and there are relatively few studies
on switching and long-term safety of these biosimilars.
Interestingly, increased patient acceptability was the least
important factor for physicians and pharmacists, but
nurses were more interested in patients’ acceptability and
adherence to their treatment.
Conclusion
There is a variance in the level of understanding and atti-
tude to biosimilars between professions, with a good level
of understanding in medical consultants and pharmacists,
but a lower level for nurses. Physicians and pharmacists
had less concerns about initiating biosimilars than nurses,
but all HCPs had high level of concerns in relation to
switching.
Declarations
Conflict of interest
The Author(s) declare(s) that they have no conflicts of
interest to disclose.
Figure 1 Respondents were asked ‘how concerned are you about safety and efficacy when considering starting or switching to biosimilars?’
International Journal of Pharmacy Practice 2018, , pp. – © 2018 Royal Pharmaceutical Society
Mohammed I. Aladul et al. 3
Funding
This research received no specific grant from any funding
agency in the public, commercial or not-for-profit sectors.
Acknowledgements
The authors would like to acknowledge all participating
associations and societies committees, everyone who pro-
vided assistance in the dissemination of the survey, and
all participants who completed the questionnaire. The
authors would like to thank Zoe Swaine and Jonathan
Underhill who participated in the pilot study.
Mohammed Aladul was sponsored by the Higher Com-
mittee for Education Development in Iraq.
This research was approved by the Independent Peer
Review Committee at Keele University.
Authors’ contributions
Contributors All authors have contributed to this study,
reviewed and approved the final version of the manu-
script. SRC designed the study, interpreted the results and
reviewed the manuscript and corrected the final version
of the manuscript.RWF participated in the study design,
interpreted the results and reviewed the manuscript and
corrected the final version of the manuscript. MIA partic-
ipated in the study design, data collection and interpreta-
tion of results, prepared the manuscript draft, and
performed all analytical testing and manuscript review.
References
1. Owens DR et al. The emergence of
biosimilar insulin preparations—a
cause for concern? Diabetes Technol
Ther 2012; 14: 989–996.
2. European Medicine Agency. Euro-
pean public assessment reports,
http://www.ema.europa.eu/ema/index.
jsp?status=Authorised&alreadyLoaded
=true&searchTab=searchByAuthType
&searchType=name&curl=pages%2F
medicines%2Flanding%2Fepar_searc
h.jsp&searchGenericType=biosimilars
&keyword=Enter+keywords&mid=W
C0b01ac058001d124&pageNo=1
2018, (accessed 4 February 2018).
3. Grabowski D et al. Attitudes towards
subsequent entry biologics/biosimi-
lars: A survey of Canadian rheuma-
tologists. Clin Rheumatol 2015; 34:
1427–1433. https://doi.org/10.1007/
s10067-014-2835-4.
4. Cohen H et al. Awareness, knowl-
edge, and perceptions of biosimilars
among specialty physicians. Adv Ther
2017; 33: 2160–2172.
5. Salem L, Harvie B. Biosimilar
medicines and their use: the nurses’
responsibility. Ren Soc Aust J 2010; 6:
76–80.
6. Wiedenmayer K et al. Developing Phar-
macy Practice: A Focus on Patient Care.
Geneve: WHO, 2006 Netherlands.
7. NICE. Biosimilar medicines. https://
www.nice.org.uk/advice/ktt15/resourc
es/biosimilar-medicines-58757954414
533. 2016, (accessed 22 June 2017).
8. The Association of the British Phar-
maceutical Industry. EBE, EFPIA and
IFPMA launch position paper on
biosimilar switching decisions, http://
www.abpi.org.uk/media-centre/Partne
r-organisation-statements/Pages/EBE-
EFPIA-and-IFPMA-launch-position-pa
per-on-biosimilar-switching-decisions.
aspx 2017, (accessed 22 June 2017).
9. Beck M et al. Knowledge, behaviors
and practices of community and hos-
pital pharmacists towards biosimilar
medicines: results of a French web-
based survey. MAbs 2017; 9: 383–390.
10. Zelenetz AD et al. NCCN biosimilars
white paper: regulatory, scientific,
and patient safety perspectives. J Natl
Compr Canc Netw 2011;9(Suppl 4):
S1–S22.
© 2018 Royal Pharmaceutical Society International Journal of Pharmacy Practice 2018, , pp. –
4 Healthcare professionals’ views on biosimilars
